Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | BHMT | Q93088 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17852438 | 1.00 | ARG1 (0.42) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL20192950 | 0.80 | ARG1 (0.44) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17852295 | 0.78 | ARG1 (0.42) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL20178599 | 0.78 | ARG1 (0.42) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL16448214 | 0.78 | ARG1 (0.42) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL20192792 | 0.78 | ARG1 (0.42) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL16447139 | 0.78 | ARG1 (0.42) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL15618178 | 0.77 | DDAH1 (0.43) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL16446671 | 0.77 | NOS3 (0.40) | NOS2NOS1NOS3GRIK1GRIK2 | |
| SCHEMBL1700571 | 0.77 | ARG1 (0.37) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030545-B1 | AMINO ACID DERIVATIVES | MEDIMMUNE LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-3030545-A2 | AMINO ACID DERIVATIVES | Medimmune Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019192-A2 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176811-A1 | Amino Acid Derivatives | BCAT2, BCAT1, DAO | ARG1 102/4885ARG2 277/4885NOS2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.